Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs 22nd Century Group Inc (XXII) Price & Performance

JPMorgan Nasdaq Equity Premium Income ETFTrade
22nd Century Group IncTrade

Price performance (Past 24H)

Key statistics

JPMorgan Nasdaq Equity Premium Income ETF vs 22nd Century Group Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.3, while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). Which is the better fit depends on your goals.

JEPQXXII
Sector
Income / Options OverlayTechnology
52-Week High
$61.46$1.07K
52-Week Low
$53.77$3.90
Market Cap
$1.49M
Enterprise Value
-$6.74M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ trades at $58.59, up 0.14% with a bearish technical signal from moving averages. The ETF focuses on Nasdaq-100 exposure with covered-call strategies, generating monthly income through dividends. Recent distributions include $0.64, $0.56, and $0.59 per share, highlighting its income-oriented approach. Technical indicators show neutral oscillators but overall bearish momentum with key support at $57.

The outlook remains cautious due to technical bearishness and capped upside from covered calls. Investment appeal centers on high distribution yields for income-focused investors, though performance may lag pure Nasdaq-100 ETFs during rallies. Risks include strategy underperformance in bull markets and dependency on options income sustainability.

22nd Century Group Inc

XXII trades at $4.32, down 0.23% with bearish technical signals. The company shows negative profitability with -65.76% net income margin and -130.19% ROE, though valuation ratios appear low with P/S of 0.03. Recent corporate actions include a 20:1 reverse stock split in June 2026. The company is expanding VLN product distribution in key markets including California and New York, supported by positive FDA regulatory developments.

While analyst consensus is 75% buy-rated, fundamental challenges persist with consistent revenue declines and negative cash flow from operations. Investment opportunity lies in successful VLN brand expansion and regulatory approvals, but risks include ongoing losses, competitive tobacco market pressures, and execution uncertainty in scaling reduced-nicotine products.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About JPMorgan Nasdaq Equity Premium Income ETF

JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.

Read more on JEPQ

About 22nd Century Group Inc

22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.

Read more on XXII